<DOC>
	<DOCNO>NCT00179647</DOCNO>
	<brief_summary>Subjects qualify participation receive lenalidomide without dexamethasone 4 week cycle disease progression document lenalidomide becomes commercially available indication multiple myeloma .</brief_summary>
	<brief_title>Expanded Access Program : Lenalidomide With Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma</brief_title>
	<detailed_description>This multicenter , non-randomized , open-label , uncontrolled , single-arm treatment study lenalidomide monotherapy combination dexamethasone subject previously treat relapsed refractory multiple myeloma , measurable myeloma paraprotein serum and/or urine . Subjects met eligibility criterion enrol study . Screening procedure take place within 28 day first dose . Subjects qualified participation receive oral lenalidomide dose 25 mg daily 21 day every 28 day . Subjects follow option dexamethasone treatment discretion treat physician : Option A : No dexamethasone . Option B : Oral pulse dexamethasone administer dose 40 mg daily Days 1-4 , 9-12 , 17-20 28-day cycle . Option C : Oral pulse dexamethasone administer dose 20 mg daily Days 1-4 , 9-12 , 17-20 28-day cycle . Option D : Oral dexamethasone administer dose 40 mg weekly Days 1 , 8 , 15 , 22 28-day cycle cycle . Treatment continue tolerated disease progression develop . Doses lenalidomide allow reduce first 25 mg 15 mg 5-mg decrement due lenalidomide toxicity . Subjects could tolerate daily dose 5 mg 21 day every 28 day discontinue treatment . At discretion investigator , dose dexamethasone modify due dexamethasone toxicity . Dose reduction discontinuation scheme dexamethasone varied accord treatment option administer . Study visit occur every 2 week first 3 cycle therapy every 4 week third cycle disease progression document , study drug discontinue another reason , lenalidomide become commercially available indication .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Must understand voluntarily sign informed consent form . 2 . Must &gt; = 18 year age time sign informed consent form . 3 . Must able adhere study visit schedule protocol requirement . 4 . Must diagnose multiple myeloma progress least 2 cycle antimyeloma treatment relapse progressive disease treatment . 5 . Subjects may previously treat thalidomide and/or radiation therapy . In addition , radiation therapy initiate prior baseline ( Day 1 ) may give concurrently study therapy , provide eligibility criterion satisfy . 6 . Measurable level myeloma paraprotein serum ( &gt; /=0.5 g/dL ) urine ( &gt; /=0.2 g excrete 24hour collection sample ) . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . 8 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study medication . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant lactating female . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm3 ( 1.0 x 109/L ) 2 . Platelet count &lt; 75,000/mm3 ( 75 x 109/L ) subject &lt; 50 % bone marrow nucleate cell plasma cell . 3 . Platelet count &lt; 30,000/mm3 ( 30x109/L ) subject &gt; /= 50 % bone marrow nucleate cell plasma cell . 4 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 5 . Serum glutamic oxaloacetic transaminase ( SGOT , aspartate transaminase [ AST ] ) serum glutamic pyruvic transaminase ( SGPT , alanine transaminase [ ALT ] ) &gt; 3.0 x upper limit normal ( ULN ) 6 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) 5 . Prior history malignancy multiple myeloma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; /= 1 year . 6 . Known hypersensitivity thalidomide dexamethasone . 7 . Prior history uncontrollable side effect dexamethasone therapy . 8 . The development desquamate rash take thalidomide . 9 . Use standard/experimental antimyeloma drug therapy within 28 day initiation study drug treatment use experimental nondrug therapy ( e.g. , donor leukocyte/mononuclear cell infusion ) within 56 day initiation study drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC5013</keyword>
	<keyword>celgene</keyword>
	<keyword>cc-5013</keyword>
	<keyword>relapsed/refractory</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>